XERS vs CORT

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus 12. 8% for Corcept Therapeutics Incorporated (CORT). Corcept Therapeutics Incorporated (CORT) offers the better valuation at 62. 3x trailing P/E (136. 0x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Corcept Therapeutics Incorporated (CORT) is the cheapest at 62.

3x versus Xeris Biopharma Holdings, Inc. at 2071. 9x. On forward P/E, Xeris Biopharma Holdings, Inc. is actually cheaper at 55. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +141.

9%, compared to +104. 0% for Xeris Biopharma Holdings, Inc. (XERS). Over 10 years, the gap is even starker: CORT returned +929. 2% versus XERS's -67. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xeris Biopharma Holdings, Inc.

(XERS) is the lower-risk stock at 1. 04β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 71% more volatile than XERS relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus 12. 8% for Corcept Therapeutics Incorporated (CORT). On earnings-per-share growth, the picture is similar: Xeris Biopharma Holdings, Inc. grew EPS 100. 9% year-over-year, compared to -33. 3% for Corcept Therapeutics Incorporated. Over a 3-year CAGR, XERS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.

1% net margin versus 0. 2% for Xeris Biopharma Holdings, Inc. — meaning it keeps 13. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XERS leads at 8. 5% versus 5. 9% for CORT. At the gross margin level — before operating expenses — CORT leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Xeris Biopharma Holdings, Inc.

(XERS) trades at 55. 3x forward P/E versus 136. 0x for Corcept Therapeutics Incorporated — 80. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 40. 4% to $71. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Corcept Therapeutics Incorporated (CORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+929.

2% 10Y return). Both have compounded well over 10 years (CORT: +929. 2%, XERS: -67. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XERS is a small-cap high-growth stock; CORT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.